-
摘要: 随机临床试验(RCT)结果对心力衰竭(心衰)的病理生理机制提出了挑战，钠-葡萄糖协同转运蛋白-2(SGLT2)抑制剂跨越了神经激素机制对心衰的认识。基于RCT和基础研究证据，本文将探索免疫代谢炎症和心肌细胞信号通路障碍在心衰发病机制中的作用，为心衰防治提供新的靶向治疗方案。Abstract: Recent results of randomized clinical trials (RCT) pose a challenge to the pathophysiology of heart failure(HF). The positive impact of sodium-glucose co-transporter 2(SGLT-2) inhibitors on HF offers new insight into HF beyond the understanding of neurohormonal mechanisms. Based on current evidence from RCTs and basic researches, in this article, we will explore the role of immunometabolic inflammation and dysfunction of the myocardial cell signaling pathway in the pathogenesis of HF, which would provide a new targeted therapy for HF.
-
Key words:
- heart failure /
- neurohormonal /
- immunometabolism /
- inflammation /
- cell signaling pathways
-
-
图 1 SGLT2抑制剂治疗慢性心衰的潜在作用机制[5]
Figure 1. The potential mechanism of SGLT2 inhibitors in the treatment of chronic heart failure
-
[1] Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction[J]. Curr Heart Fail Rep, 2013, 10(4): 401-410. doi: 10.1007/s11897-013-0155-7
[2] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726.
[3] McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37): 3627-3639. doi: 10.1093/eurheartj/ehad195
[4] 中国心力衰竭中心联盟专家委员会. 心力衰竭SGLT2抑制剂临床应用的中国专家共识[J]. 临床心血管病杂志, 2022, 38(8): 599-605. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.08.001
[5] 廖梦阳, 廖玉华, 余淼, 等. SGLT2抑制剂治疗心力衰竭潜在机制的新认识[J]. 临床心血管病杂志, 2022, 38(1): 1-6. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.01.001
[6] Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in Heart Failure: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2020, 75(11): 1324-1340.
[7] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2020, 382(20): 1883-1893.
[8] 廖玉华, 杨杰孚, 张健, 等. 舒张性心力衰竭诊断和治疗专家共识[J]. 临床心血管病杂志, 2020, 36(1): 1-10. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2020.01.001
[9] Díaz-Rodríguez E, Agra RM, Fernández ÁL, et al. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability[J]. Cardiovasc Res, 2018, 114(2): 336-346. doi: 10.1093/cvr/cvx186
[10] Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study[J]. JACC Heart Fail, 2021, 9(8): 578-589. doi: 10.1016/j.jchf.2021.04.014
[11] Everett BM, Cornel JH, Lainscak M, et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure[J]. Circulation, 2019, 139(10): 1289-1299. doi: 10.1161/CIRCULATIONAHA.118.038010
[12] Abbate A, Wohlford GF, Del Buono MG, et al. Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials[J]. Eur Heart J Cardiovasc Pharmacother, 2022, 8(5): 503-510. doi: 10.1093/ehjcvp/pvab075
[13] van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction[J]. Circulation, 2012, 126(7): 830-839. doi: 10.1161/CIRCULATIONAHA.111.076075
[14] Emdin M, Aimo A, Castiglione V, et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week[J]. J Am Coll Cardiol, 2020, 76(15): 1795-1807. doi: 10.1016/j.jacc.2020.08.031
[15] Aimo A, Castiglione V, Borrelli C, et al. Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies[J]. Eur J Prev Cardiol, 2020, 27(5): 494-510. doi: 10.1177/2047487319870344
[16] Chatre L, Ducat A, Spradley FT, et al. Increased NOS coupling by the metabolite tetrahydrobiopterin(BH4) reduces preeclampsia/IUGR consequences[J]. Redox Biol, 2022, 55: 102406. doi: 10.1016/j.redox.2022.102406
[17] Scioli MG, Storti G, D'Amico F, et al. Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets[J]. J Clin Med, 2020, 9(6): 1995. doi: 10.3390/jcm9061995
[18] Koskenkorva-Frank TS, Weiss G, Koppenol WH, et al. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress[J]. Free Radic Biol Med, 2013, 65: 1174-1194. doi: 10.1016/j.freeradbiomed.2013.09.001
[19] Singh J, Lee Y, Kellum JA. A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach[J]. Crit Care, 2022, 26(1): 246. doi: 10.1186/s13054-022-04075-0
[20] Kolijn D, Kovács Á, Herwig M, et al. Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase(sGC)Activator[J]. Front Physiol, 2020, 11: 345. doi: 10.3389/fphys.2020.00345
[21] Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA(Vericiguat Global Study in Subjects with HFrEF)trial[J]. Eur J Heart Fail, 2021, 23(8): 1313-1321.
[22] Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial[J]. Eur J Heart Fail, 2021, 23(8): 1300-1312. doi: 10.1002/ejhf.2285
[23] Senni M, Alemayehu WG, Sim D, et al. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial[J]. Eur J Heart Fail, 2022, 24(9): 1614-1622. doi: 10.1002/ejhf.2608
[24] Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study[J]. JACC Heart Fail, 2020, 8(11): 931-939. doi: 10.1016/j.jchf.2020.08.008
-
下载:
图(3)
计量
- 文章访问数: 912
- PDF下载数: 437
- 施引文献: 0